Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2016

View Archived Issues

Sapience completes series A financing

Inotek initiates phase II trial of trabodenoson/latanoprost FDC in glaucoma

Redx Pharma discovers novel bacterial topoisomerase inhibitors

Vaccine Technologies HIV vaccine LFn-p24B/C displays immunogenicity in phase I study

Redhill Biopharma signs collaboration agreement with NIAID

Faes Farma patents H1 receptor antagonists

Bioaffinity Technologies renews collaboration with University of Texas

Bristol-Myers Squibb discloses RIP-3 inhibitors

Muses Labs partners with Metabolon to apply metabolomics to Alzheimer's disease

Daiichi Sankyo develops retinoid RORgamma t antagonists and IL-17 production inhibitors

Boehringer Ingelheim and Eli Lilly collaborate on phase Ib trial for BI-836845

CytRx announces initial phase III results for aldoxorubicin in soft tissue sarcoma

Mologen enrolls first patient in phase I study for lefitolimod with ipilimumab

Novel macrolides show promise against macrolide-resistant Gram-positive isolates

FDA grants priority review to NDA for chewable tablet presentation of mebendazole

Scynexis sells cyclophilin inhibition assets to Cypralis

Invasive lobular breast carcinoma model created using CRISPR/Cas9 somatic gene editing

Avacta and Glythera collaborate to develop targeted biotherapeutics as alternative to ADCs

FDA grants breakthrough therapy designation to LOXO-101

MRIGlobal receives DTRA contract award to support development of tularemia vaccine

TARIS Biomedical starts phase Ib trial for TAR-200

Alere's rapid point-of-care fourth-generation HIV test receives WHO prequalification

Amgen and Daiichi Sankyo sign Japanese biosimilar commercialization agreement

Urolithin A improves muscle function; Amazentis conducts clinical trial

Evelo and Epiva merge to create immuno-microbiome company

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...